The 15-LOX-1 pathway has been demonstrated to generate eoxines in eosinophils, mast cells, and nasal polyps from allergic subjects, indicating that inhibition of 15-LOX-1 might be an attractive target for the treatment of inflammatory respiratory disorders such as asthma, rhinitis, and chronic obstructive pulmonary disease (COPD) in humans. Here, ALOX15 is linked to nasal cavity polyp.